Before you sell to, join or invest in Maxymune Therapeutics, Inc.
MentionFox check on Maxymune Therapeutics, Inc.: only 2 sources on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/maxymune-therapeutics-inc-form-d-25000001
Check Maxymune Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Maxymune Therapeutics, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
Maxymune Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-02-28.
Maxymune Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on February 28, 2025. The filing reports $2.67M sold. Its industry group is Biotechnology. It names Gordon Ringold (Executive Officer, Director), Neil Solomons (Director), Tatjana Naranda (Executive Officer, Director) (SEC Form D/A, February 28, 2025).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like Maxymune Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Maxymune Therapeutics, Inc.
Free to see. No signup.
Get an email when Maxymune Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Maxymune Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Maxymune Therapeutics, Inc. →Get the full cited report on Maxymune Therapeutics, Inc.
What the filing shows about Maxymune Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maxymune Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Maxymune Therapeutics, Inc.'s address as 95 Main St., Suite 9, Los Altos, CA 94022.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Maxymune Therapeutics, Inc. →
Amended on 2026-06-03: the offering size changed from $2,500,000 to $4,500,000; the amount sold changed from $850,000 to $2,675,000; the number of investors changed from 8 to 15. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Maxymune Therapeutics, Inc. See pricing
Maxymune Therapeutics, Inc. is a registered filer with the SEC (CIK 2058052) and has filed since 2025-02-28. 2 filings are on record, the latest on 2026-06-03.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Maxymune Therapeutics, Inc.'s Form D of 2025-02-28 names Gordon Ringold, Neil Solomons and Tatjana Naranda as its officers, directors or promoters.
Its new offerings report $850K sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
Gordon Ringold is named as Executive Officer and Director on the Form D that Maxymune Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 3 people that filing names.
Neil Solomons is named as Director on the Form D that Maxymune Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 3 people that filing names.
Tatjana Naranda is named as Executive Officer and Director on the Form D that Maxymune Therapeutics, Inc. filed with the SEC on 28 February 2025, one of 3 people that filing names.
3 people named on the filing — 2 holding an executive role and 1 as a director only.
Named as of the 2025-02-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Maxymune Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maxymune Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maxymune Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Maxymune Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Maxymune Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Maxymune Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/maxymune-therapeutics-inc-form-d-25000001